@markie125
thank you responding... hard stats on the main cancers BD1 are focusing on currently (not including possible transfer of thier tests into other cancers) is a tick over 22b revenue and at the moment there's zero players that are at the stage BD1 is (unless you know of others) obviously they wont own the entire market but if you use the example of cochlear then there is no reason why they cant hold 64% share as cochlear does.
the market they are targeting is growing at an average rate of 32% and will continue to grow.
you are spot on when you say its how they GTM but unless something happens that causes these tests to fail they will be the dominant player for decades to come.
@markie125 thank you responding... hard stats on the main...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
0.005(1.02%) |
Mkt cap ! $45.54M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 50.0¢ | 49.0¢ | $15.36K | 31.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 11463 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
49.5¢ |
Change
0.005 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 49.5¢ | 49.5¢ | 49.5¢ | 180 | ||
| Last updated 13.19pm 03/05/2024 ? | |||||
| IIQ (ASX) Chart |